Mission Bio Launches Innovative Single-cell Genome Integrity Solution to Measure Whole Genome Copy Number Variation in Advanced Therapies and Tumor Samples

First-of-its-kind DNA assay unlocks high-throughput CNV insights critical to cell and gene therapy (CGT) safety and characterizing tumor heterogeneity

Excerpt from the Press Release:

SAN FRANCISCO, Calif., Sep. 26, 2024 – Mission Bio, a leader in single-cell multiomics solutions for precision medicine, today announced the launch of its Tapestri® Genome Integrity CNV Solution. The new product is the only single-cell high-throughput solution for measuring genome-wide copy number variants (CNVs) on the market and is designed to fulfill important needs in the critical areas of therapeutic development oncology research.

Gene-editing-based and stem cell therapies continue to hold tremendous promise for hard-to-treat diseases but have encountered safety questions associated with genomic stability. The latest FDA guidance suggests that assessment of genomic integrity include chromosomal abnormalities like CNVs (i.e., duplications and deletions) as indicators of clinical safety. Conventional methods such as g-banding fail to provide adequate answers due to their low throughput, as they may not analyze enough cells to detect aberrations. Oncology researchers have faced similar issues unlocking the potential of CNVs to serve as prognostic or therapeutic markers associated with tumor evolution, immune evasion, and therapeutic resistance. Existing bulk techniques provide only a limited view of CNV-based clonal architecture.

Mission Bio’s Tapestri Genome Integrity CNV Solution enables both CGT developers and oncology researchers with high-throughput, single-cell multiomic analysis of genome-wide CNVs, combined with automated reporting and multiplexing capabilities to ensure even more accessibility. Compared to current methods, the solution equips CGT developers with improved assay throughput to uncover potentially adverse chromosomal events, while simultaneously measuring genome editing outcomes. For oncology researchers, the solution enables the assessment of cell-to-cell aneuploidy and CNV events across the genome with the potential to co-measure SNVs and focal CNVs. Tapestri enables these researchers the rapid characterization of clonal heterogeneity behind tumorigenesis and therapy resistance.

Click the button below to read the entire Press Release:

Continue Reading The Press Release